Verona Pharma PLC (VRNA)
38.81
+0.95
(+2.51%)
USD |
NASDAQ |
Nov 22, 16:00
38.79
-0.02
(-0.05%)
After-Hours: 20:00
Verona Pharma Cash from Operations (Quarterly): -62.66M for Sept. 30, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -62.66M |
| June 30, 2024 | -17.10M |
| March 31, 2024 | -13.61M |
| December 31, 2023 | -10.40M |
| September 30, 2023 | -12.73M |
| June 30, 2023 | -21.31M |
| March 31, 2023 | -5.782M |
| December 31, 2022 | -7.738M |
| September 30, 2022 | -18.10M |
| June 30, 2022 | -19.52M |
| March 31, 2022 | -14.51M |
| December 31, 2021 | -17.32M |
| September 30, 2021 | 22.82M |
| June 30, 2021 | -20.20M |
| March 31, 2021 | -18.55M |
| December 31, 2020 | -18.80M |
| Date | Value |
|---|---|
| September 30, 2020 | -9.996M |
| June 30, 2020 | -3.061M |
| March 31, 2020 | -13.22M |
| December 31, 2019 | -11.55M |
| September 30, 2019 | -8.403M |
| June 30, 2019 | -10.05M |
| March 31, 2019 | -12.86M |
| December 31, 2018 | -5.970M |
| September 30, 2018 | -0.8708M |
| June 30, 2018 | -7.40M |
| March 31, 2018 | -8.740M |
| December 31, 2017 | -6.821M |
| September 30, 2017 | -10.54M |
| June 30, 2017 | -6.203M |
| March 31, 2017 | -4.408M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-62.66M
Minimum
Sep 2024
22.82M
Maximum
Sep 2021
-14.67M
Average
-14.06M
Median
Cash from Operations (Quarterly) Benchmarks
| TC BioPharm (Holdings) PLC | -3.055M |
| Adaptimmune Therapeutics PLC | -54.45M |
| Biodexa Pharmaceuticals PLC | -- |
| NuCana PLC | -1.446M |
| Autolus Therapeutics PLC | -76.74M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Financing (Quarterly) | -7.087M |
| Free Cash Flow | -103.81M |
| Free Cash Flow Per Share (Quarterly) | -0.7688 |
| Free Cash Flow to Equity (Quarterly) | -62.98M |
| Free Cash Flow to Firm (Quarterly) | -57.49M |
| Free Cash Flow Yield | -3.31% |